Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Sponsor: Calibr, a division of Scripps Research
Summary
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
Official title: A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2021-01-21
Completion Date
2025-10-06
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
CLBR001 and SWI019
No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
Locations (8)
City of Hope National Medical Center
Duarte, California, United States
University of California at San Diego
San Diego, California, United States
University of Chicago
Chicago, Illinois, United States
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Weill Cornell Medical College - New York Presbyterian Hospital
New York, New York, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, United States
Sarah Cannon Research Institute - Texas Transplant Institute
San Antonio, Texas, United States